An emerging clinical research market with a large and accessible patient population
Uzbekistan is one of Central Asia's most promising emerging clinical research destinations. With a population of over 37 million, a large proportion of whom are treatment-naive for many conditions, Uzbekistan offers sponsors access to patient cohorts that are difficult to find in more saturated Western markets. Combined with a rapidly modernising healthcare system and an improving regulatory framework, the country presents compelling opportunities for international clinical trials.
aCROss Medical has established a local operational infrastructure in Uzbekistan, with experienced site relationships in Tashkent and regional centres. Our team guides sponsors through every regulatory step and manages all aspects of study delivery from submission to close-out.
Clinical trials in Uzbekistan are regulated by the Ministry of Health and the Agency for the Development of Pharmaceutical Industry. The regulatory framework has been significantly reformed in recent years to align with international GCP standards, with the government actively encouraging foreign pharmaceutical companies to conduct research in the country. aCROss Medical's regulatory team has direct experience navigating the submission and approval process and can provide sponsors with realistic timelines and full support.
Our Uzbek sites have particular strength in cardiology, endocrinology, infectious diseases, nephrology and oncology — therapeutic areas where the country's patient demographics and disease burden create strong recruitment potential. The country's large, multi-ethnic population also makes it valuable for studies requiring demographic diversity.
aCROss Medical provides sponsors with end-to-end operational support in Uzbekistan: regulatory submission, ethics committee coordination, site activation, patient recruitment support, clinical monitoring, data management and pharmacovigilance. Our team is on the ground and in constant communication with sponsor teams, ensuring full transparency at every stage of the study.